TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Bioenergetics in TBI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have moderate to severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) to be enrolled in the TBI or TBI with trauma groups.~* Patients enrolled in the TBI with polytrauma group must also exhibit polytrauma including concomitant traumatic brain injury, major trauma to the chest, abdomen, pelvis or extremities.~* Patients must be greater than or equal to 18 years of age and must be less than or equal to 50 years of age.~* Patients must be able to cooperate for a detailed neurologic exam.~* Patients must be consented and undergo first blood sampling within the first 12 hours (+/- 2 hours) after their traumatic brain injury to be enrolled in the TBI or TBI with trauma groups.~* Patients must be expected to survive to discharge, as assessed by their admitting neurosurgery team~Exclusion Criteria:~* For the control group only, patients who have experienced a TBI in the last 6 months.~* Diagnosis of platelet diseases or disorders, such as thrombocytopenia, thrombocytosis, or Von Willebrand disease.~* Platelet transfusion within the last six months.~* Comorbid regimen of Metformin within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- TBI without polytrauma (Type: None): Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) within the last 12 hours, without additional polytrauma.
- TBI with polytrauma (Type: None): Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) and polytrauma, including major trauma to the chest, abdomen, pelvis or extremities. within the last 12 hours.
- Healthy Control (Type: None): Subjects who have not experienced any TBIs within the last six months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Meets the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria for Systemic Lupus Erythematosus (SLE)~* Renal biopsy confirming a histologic diagnosis of active Lupus Nephritis (LN) International Scociety of Nephrology/Renal Pathology Society (ISN/RPS) Classes III, IV-S, or IV-G; or Class V~* Urine protein:creatinine ratio (UPCR) ≥1.5 mg/mg or UPCR ≥1 mg/mg assessed with a 24-hour urine specimen~Exclusion Criteria:~* Pure ISN/RPS Class V membranous LN~* Screening estimated glomerular filtration rate ≤30 mL/min/1.73 m\^2~* Dialysis within 12 months before screening or plans for dialysis within 6 months after enrollment in the study~* End-stage renal disease~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BMS-986165 Dose 1 (Type: EXPERIMENTAL): Specified Dose on Specified Days
- BMS-986165 Dose 2 (Type: EXPERIMENTAL): Specified Dose on Specified Days
- Placebo for BMS-986165 (Type: PLACEBO_COMPARATOR): Specified Dose on Specified Days
- Mycophenolate Mofetil (MMF) (Type: EXPERIMENTAL): Specified Dose on Specified Days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Simultaneously Using Traditional Chinese Medicine (Si-Ni-Tang) to Treat Septic Shock Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients admitted to our intensive care units are enrolled if their disease diagnosis meets the definition of septic shock~* Using vasopressor now and the duration from initiation of vasopressor use to the entrance of the study is within 24 hours~* Nasogastric tube feeding~Exclusion Criteria:~* More than one kind of vasopressor is administrated~* Patients with extremely poor gastrointestinal function and can not tolerate diet feeding~* Acute myocardial infarction~* Patients with evidence of major bleeding~* Expected surgical intervention or scheduled surgery in the subsequent one week~* Patients who received digoxin for arrhythmia in the past one week

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Si-Ni-Tang (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: SUCCESS Tracking Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult males and females between the ages of 18 - 69 years~* BMI ( \> 25.0 kg/m2)~* Beginning a weight loss diet plan (MD, TSFL, or one of a number of commercially available plans)NOTE: subjects must have already committed to a weight-loss plan in order to be eligible for this study. The recruitment process is specifically designed so as NOT to appear to encourage subjects to begin a weight-loss plan. Rather, the purpose of this research is to track information about persons who have already committed to a weight-loss program.~* Willing and able to give informed consent~* Willing and able to comply with study protocol~Exclusion Criteria:~* Unable to give informed consent~* Previous hospitalization for psychiatric disorder or eating disorder~* Current, uncontrolled medical conditions~* Taking unstable doses of weight-loss or appetite-affecting medications (e.g., SSRIs, steroids, Ritalin)~* Taking prescription weight-loss drugs (Phentermine, Sibutramine, Orlistat, etc...)~* Have undergone, or plan to undergo, weight loss surgery (e.g. gastric bypass, lap band, duodenal switch) in the next 6 1/3 years~* Plan to undergo weight-altering cosmetic surgery procedures (e.g. breast reduction/augmentation, tummy tuck, liposuction, or other skin removal procedures) in the next 6 1/3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Other Dieters (OD) (Type: None): Those participating in weight loss programs other than Medifast Direct or Take Shape For Life.
- Take Shape For Life (TSFL) (Type: None): Those using Medifast meal replacement products for weight loss while working closely with a Take Shape For Life certified Health Coach.
- Medifast Direct (MD) (Type: None): Those using Medifast meal replacement products specifically for weight loss that were purchased directly from the company and individually monitored by the customer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of NAC in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to perform reproducible spirometry according to ATS criteria~* Clinical history consistent with moderate to severe asthma for 1 year or greater.~* Post-bronchodilator FEV1 \<90% of predicted~* Prescription and daily use of inhaled corticosteroid (ICS) equivalent to 240mcg of beclomethasone or greater and a second asthma controller therapy.~* CT mucus score \>3 (determined during the initial screening process, provided the prior two conditions are met)~* Written informed consent obtained from participant and ability for participant to comply with the requirements of the study.~Exclusion Criteria:~* Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.~* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.~* History of intolerance to study medications.~* Current use of carbamazepine~* Angina which includes a treatment plan with PRN nitroglycerin or nitrites~* Smoking of tobacco or other recreational inhalants in last year and/or \>10 pack-year smoking history~* Current participation in an investigational drug trial Concurrent Medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 20% n-acetylcystine (NAC) (Type: EXPERIMENTAL): NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
- 0.9% saline (Type: PLACEBO_COMPARATOR): Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma) that is recurrent or progressive or with residual tumor after standard therapy, including radiotherapy~* Measurable tumor by MRI scan performed within two weeks prior to study entry~* Male or female patients~* Children 6 months to 17 years~* Performance status: Karnofsky 60-100%~* Life expectancy of at least 2 months~* WBC greater than 1,500/mm\^3~* Platelet count greater than 50,000/mm\^3~* No evidence of hepatic or renal insufficiency and a total bilirubin and serum creatinine no greater than 2.5 mg/dL and SGOT/SGPT no greater than 5 times upper limit of normal~* Must have recovered from adverse effect of previous therapy~* At least 8 weeks elapsed since last dose of radiation~* At least 4 weeks elapsed since last dose of chemotherapy (6 weeks for nitrosoureas)~* Corticosteroids permitted using the smallest dose that is compatible with preservation of optimal neurologic function~* Acceptable methods of birth control (in females of child-bearing potential or in sexually active males)during and up to four weeks following completion of study~Exclusion Criteria:~* Prior A10 and AS2-1 treatment~* Severe heart disease~* Uncontrolled hypertension~* Lung disease~* Hepatic failure~* Serious active infections, fever or other serious concurrent disease that would interfere with the evaluation of the treatment drug.~* Pregnant or nursing~* Serious concurrent disease~* Concurrent antineoplastic or immunomodulatory agents

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cycloserine in the Treatment of Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe obstructive or central sleep apnea (Apnea Hypopnea Index \> 30/hr).~* Minimum Oxygen saturation during respiratory events \>70% throughout sleep during the clinical sleep study.~Exclusion Criteria:~* Contraindication to the use of cycloserine, namely history of allergy to cycloserine, seizures, depression, severe anxiety or psychosis, excessive use of alcohol or renal failure.~* Past or current history of tuberculosis~* Hypercapnia \> 55 millimeters of mercury during the diagnostic clinical sleep study.~* Neuromuscular disease.~* Obesity-hypoventilation syndrome.~* Pregnancy.~* Significant co-morbidities: Dialysis-dependant renal failure, severe asthma or chronic lung disease, congestive heart failure, previous stroke.~* Recent (within 3 months) myocardial infarction or Active coronary ischemia event.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cycloserine (Type: ACTIVE_COMPARATOR): Cycloserine, 250 mg capsules by mouth, one hour prior to initiation of sleep study, single dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, sugar capsule by mouth, one hour prior to initiation of sleep study, single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of 18 to 80 years of age with American Society of Anesthesiologists (ASA) physical status classification of 1, 2 or 3~* Scheduled to undergo unilateral total knee arthroplasty (TKA) for the treatment of the osteoarthritis.~Exclusion Criteria:~* Subjects who have pain or disability in a site other than the operative joint.~* Subjects who have had total knee arthroplasty within 6 months of the scheduled surgery or are scheduled to undergo bilateral knee arthroplasty.~* Subjects whose body mass index (BMI) is 40 or more.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BTDS 10 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
- BTDS 20 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
- BTDS 30 (Type: EXPERIMENTAL): Buprenorphine transdermal patch 30 mcg/h applied for 7-day wear
- Placebo TDS (Type: PLACEBO_COMPARATOR): Placebo patches were similar to BTDS 10 and 20.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Growth and Tolerance Trial on Infant Formula With HMO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age ≥ 37 weeks~* Birth weight ≥ 2500 grams~* No recognized diseases (such as cardiac, pulmonary, gastrointestinal, renal or genetic diseases)~* Boys and girls~* Recruited \< 1 month/age~* Being available for follow up until the age of 4 months~* Exclusive formula feeding or exclusive breast feeding at time of recruitment~Exclusion Criteria:~* Gestational age \<37 weeks~* Birth weight \<2500 grams~* Severe acquired or congenital diseases, mental or physical disorders~* Illness at screening/ inclusion~* Incapability of parents/caregivers to comply with the study protocol~* Received antibiotics within the first month of life~* Not tolerating standard cow's milk based infant formula~* Participation in another clinical trial~* Maternal illicit drug use during pregnancy or post-partum period~* Parent/caregiver does not have a cell phone to use for filling out questionnaires

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Month
- Healthy Volunteers: t

Study Arms:
- Breastfed group (Type: NO_INTERVENTION): Non-randomized breastfed reference group
- Control formula (Type: PLACEBO_COMPARATOR): Group receiving standard infant formula
- Formula with HMO (Type: ACTIVE_COMPARATOR): Group receiving standard infant formula supplemented with HMO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All adult (\>=18 years of age) mechanically ventilated patients admitted to the medical, surgical, trauma, or cardiothoracic ICUs of the UPMC main campus who are expected by the ICU clinical team to require \>24 hours of mechanical ventilation~Exclusion Criteria:~* Baseline QTc \>480 milliseconds (ms); history of Parkinson's disease; pregnancy; history of schizophrenia or neurologic disease that would confound the delirium assessment; deafness or inability to understand English or Spanish; extubation prior to enrollment; previously enrolled in this study; patient, family, or attending physician refusal; death before enrollment; treatment with haloperidol within 2 days prior to ICU admission; and prisoners.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- haloperidol (Type: EXPERIMENTAL): Once diagnosed as delirious, randomized to haloperidol 5 mg IV
- placebo (Type: PLACEBO_COMPARATOR): once diagnosed as delirious, received 5 mg saline placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic kidney disease~* Age: \>18yo~* Stable Hemoglobin (Hgb) for 1 month on stable dose of erythropoietin for 1 month (defined as erythropoietin dose within 15% of previous months erythropoietin dose)~* Unchanged maintenance oral or intravenous (IV) iron therapy for 1 month~* Serum 25-hydroxy Vitamin D levels \< 30 ng/mL~* History of 25-hydroxy Vitamin D levels \< 30 ng/mL currently on ergocalciferol replacement~Exclusion Criteria:~* On hemodialysis~* Chronic kidney disease 5~* Hypercalcemic (Calcium level \> 11mg/dL)~* Pregnant female~* Iron deficient (iron saturation \< 20%, Ferritin \< 100ng/mL)~* Presence of active malignancy~* Presence of active infections~* Presence of active inflammatory properties~* Presence of blood dyscrasias~* Active bleeding or bleeding within the past 3 months (other than menses)~* B12 deficiency~* Folate deficiency~* Blood transfusion during participation~* Parathyroid levels exceeding the expected levels allowed for the stage of a subjects Chronic kidney disease (Target Parathyroid in: Chronic kidney disease 3 35-70 pg/mL, Chronic kidney disease 4 70-110 pg/mL)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ergocalciferol supplementation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolomic in Critical Ill Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with severe left or right ventricular dysfunction undergoing cardiac surgery~* patients undergoing ablation of ventricular tachycardia~* patients with febrile neutropenia after chemotherapy or allogeneic transplant for haematological diseases~* patients undergoing thoracoabdominal vascular surgery~Exclusion Criteria:~* pregnant women~* no written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- criticall ill patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues